

WHO operational handbook on tuberculosis

Module 4: Treatment

**Drug-susceptible
tuberculosis treatment**



World Health
Organization

WHO operational handbook on tuberculosis

Module 4: Treatment

**Drug-susceptible
tuberculosis treatment**

WHO operational handbook on tuberculosis Module 4: Treatment – drug-susceptible tuberculosis treatment

ISBN 978-92-4-005076-1 (electronic version)

ISBN 978-92-4-005077-8 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO operational handbook on tuberculosis Module 4: Treatment – drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <https://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design by Inis Communication

Acknowledgements	v
Abbreviations and acronyms	vi
Definitions	1
Executive summary	2
Key WHO recommendations on DS-TB	3
Treatment of DS-TB using the 6-month regimen	3
Treatment of DS-TB using 4-month regimens	3
DS-TB treatment and antiretroviral therapy in people living with HIV	3
The use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis	4
1. Introduction	5
2. Key considerations in DS-TB treatment	6
2.2 Care and support during TB treatment	7
2.3 Options in treatment of DS-TB	7
3. Treatment of DS-TB using the 6-month regimen	11
3.1 Eligibility	12
3.2 Composition and duration of the regimen 2HRZE/4HR	12
3.3 Considerations for implementation	13
3.4 Subgroups	13
3.5 Treatment monitoring	14
4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen	15
4.1 Eligibility	15
4.2 Composition and duration of the regimen	16
4.3 Considerations for implementation	16
4.4 Subgroups	17
4.5 Treatment monitoring	19
5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen	20
5.1 Eligibility	20
5.2 Composition and duration of the regimen	21
5.3 Considerations for implementation	22
5.4 Subgroups	23
5.5 Treatment monitoring	24

6. Treatment of DS-TB in PLHIV	25
6.1 Eligibility	25
6.2 Composition and duration of the regimen	25
6.3 Considerations for implementation	26
6.4 Treatment monitoring	26
7. Treatment of extrapulmonary TB	27
7.1 Eligibility	27
7.2 Composition and duration of the regimen	27
7.3 Use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis	28
7.4 Considerations for implementation	29
8. Treatment of DS-TB in special situations	30
8.1 Diabetes	30
8.2 Pregnancy	31
8.3 Older people	32
8.4 Chronic renal failure	33
8.5 Chronic liver disease	34
9. Monitoring treatment response	36
9.1 Clinical examination	36
9.2 Chest radiography	37
9.3 Sputum smear and culture	37
9.4 Assessment of patients when treatment failure is suspected	39
10. Outcome definitions	41
10.1 Treatment outcome definitions	41
10.2 Considerations for implementation	42
References	44
Annex. Dosages of anti-TB medicines by weight band for treatment of DS-TB	51
Web annexes	52
Web annex 1	52
Clinical outcomes and pharmacokinetics of first-line drugs (rifampicin, isoniazid, ethambutol and pyrazinamide) in children (aged <18 years) treated for drug-susceptible tuberculosis: systematic review and meta-analysis.	
Web annex 2	52
Optimization of dosage of the first-line medicines rifampicin, isoniazid, ethambutol and pyrazinamide in treatment of drug-susceptible tuberculosis: summary of evidence from four systematic reviews.	

Acknowledgements

The production and writing of this document, *WHO operational handbook on tuberculosis Module 4: Treatment – drug-susceptible tuberculosis treatment*, was coordinated by Fuad Mirzayev, with the support of Medea Gegia and Linh Nguyen, under the guidance of Matteo Zignol and the overall direction of Tereza Kasaeva, Director of the World Health Organization (WHO) Global Tuberculosis Programme (WHO/MTB). Significant input to finalize the document was provided by Giovanni Battista Migliori, WHO Collaborating Centre for Tuberculosis and Lung Diseases; Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy; and Lia D'Ambrosio, Public Health Consulting Group, Lugano, Switzerland. Colleagues from the WHO/MTB – Annemieke Brands, Dennis Falzon, Tiziana Masini, Sabine Verkuijl and Kerri Viney – also contributed to this handbook. The external review group comprised Anna Cristina Carvalho, Lisa Chen, Jeremiah Chakaya, Alberto Matteelli, Mario Raviglione and Simon Tiberi.

WHO acknowledges and appreciates the time and support of all those who have contributed to these efforts, and gratefully acknowledges the contribution of all experts involved in the production of this operational handbook. The development of this document was funded by grants provided to WHO by the United States Agency for International Development.

Abbreviations and acronyms

ART	Antiretroviral therapy
AUC	Area under the curve
BMI	Body mass index
CALHIV	Children and adolescents living with HIV
CI	Confidence interval
CLD	Chronic liver disease
CLHIV	Children living with HIV
CRF	Chronic renal failure
CTP	Child–Turcotte–Pugh
CXR	Chest radiography
DR-TB	Drug-resistant tuberculosis
DS-TB	Drug-susceptible tuberculosis
DST	Drug susceptibility testing
ECG	Electrocardiogram
FDC	Fixed-dose combination
GDG	Guideline Development Group
HIV	Human immunodeficiency virus
IRIS	Immune reconstitution inflammatory syndrome
MDR/RR-TB	Multidrug- or rifampicin-resistant tuberculosis
MDR-TB	Multidrug-resistant tuberculosis
NTM	Non-tuberculosis mycobacteria
NTP	National tuberculosis programme
PLHIV	People living with HIV
RCT	Randomized controlled trial
RR-TB	Rifampicin-resistant tuberculosis
SAM	Severe acute malnutrition
TR	Tuberculosis

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31183

